Eikon Therapeutics, Inc. EIKN Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Axcelis TechnologiesACLS

-$39K-106%

PDF SolutionsPDFS

$0-100%

Fastly, Inc. FSLY

$798K+27.5%

PrecigenPGEN

$369K-47.7%

Varonis SystemsVRNS

-$882K-791%

Strategic Education, Inc.STRA

$3K-96.5%

Operating income-$87.3M-22.3%

Net income-$83.0M-21.6%

EPS (diluted)-$2.46+90.9%

Cash & equivalents$161.2M-21.2%

Total debt$254.8M—

Total equity$550.7M+186%

Total assets$850.8M—

Operating cash flow-$89.8M-64.7%

CapEx$262.0K-98.8%

Free cash flow-$90.1M-17.1%

Market cap$521.35M—

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The official record: Eikon Therapeutics, Inc. ’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Eikon Therapeutics, Inc. 's accretion (amortization) of discounts and premiums, investments?: Eikon Therapeutics, Inc. (EIKN) reported accretion (amortization) of discounts and premiums, investments of $827K in Q1 2026.